Skip to main content
Fig. 3 | Alzheimer's Research & Therapy

Fig. 3

From: Amyloid-β misfolding as a plasma biomarker indicates risk for future clinical Alzheimer’s disease in individuals with subjective cognitive decline

Fig. 3

Kaplan-Meier survival curves at baseline to predict progression to clinically diagnosed MCI or AD using the structure biomarker. The unadjusted model based only on biomarker frequency is shown in a and an adjusted model including age, sex, and APOEε4 is shown in b for all three groups distinguished by the structure biomarker being < 1644 cm− 1 for high misfolding, ≥ 1644 cm− 1 and ≤ 1646 cm− 1 for low misfolding, and > 1646 cm− 1 for normal folding

Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193